The Relationship Between Circulating Fibroblast Growth Factor 23 and Bone Metabolism Factors in Korean Hemodialysis Patients

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2010 Apr 9

PMID 20376517

Citations 6

Authors

So-Youn Park

Kyung-Hwan Jeong

Ju-Young Moon

Sang-Ho Lee

Chun-Gyoo Ihm

Sang Youl Rhee

Jeong-Taek Woo

In-Hwan Oh

Tae-Won Lee

Affiliations

Soon will be listed here.

Abstract

Background: Fibroblast growth factor 23 (FGF-23) is a circulating factor that acts as a phosphaturic factor in the kidneys. It is also involved in several disorders of phosphate regulation and bone metabolism. We hypothesized that increased FGF-23 levels in patients with endstage renal disease (ESRD) on maintenance hemodialysis would be associated with increased bone demineralization, and we analyzed the relationship between FGF-23 levels and bone mineral density (BMD).

Methods: The serum level of FGF-23 was measured in this cross-sectional study, whose subjects consisted of 54 patients with ESRD on maintenance hemodialysis. Clinical parameters associated with hemodialysis and bone metabolism were measured. The relationship between serum FGF-23 and BMD and the factors affecting the serum level of FGF-23 were analyzed.

Results: Serum FGF-23 levels were significantly higher in ESRD patients on maintenance hemodialysis than in normal persons (2961.4 vs. 30 pg/ml). Multiple regression analysis showed that increasing FGF-23 levels were associated with serum phosphate (r = 0.684, P < 0.001), but not with BMD or other bone metabolism factors. Factors affecting log(10)FGF-23 included the serum calcium phosphate product (beta = 0.603) and K (t)/V (integrated fractional clearance expressed per dialysis, beta = -0.244). These results were also seen in an analysis of the correlations based on T score or gender.

Conclusions: FGF-23 levels were positively associated with serum phosphate levels but were not correlated with BMD. The only factors affecting log(10)FGF-23 were the serum calcium phosphate product and K (t)/V. These findings suggest that FGF-23 may have no direct effect on bone mineralization, and further studies are warranted to examine the effects of FGF-23 on vitamin D metabolism.

Citing Articles

Significance of changes in FGF23 levels in childhood primary nephrotic syndrome and children who progress to end‑stage renal disease.

Liu D, Yang F, Zhang S, Guo Z, Peng S Exp Ther Med. 2023; 26(2):390.

PMID: 37456167 PMC: 10347369. DOI: 10.3892/etm.2023.12089.

Serum Intact Fibroblast Growth Factor 23 Levels Are Negatively Associated with Bone Mineral Density in Chronic Hemodialysis Patients.

Lee W, Fang Y, Chen M, Liou H, Lee C, Tsai M J Clin Med. 2023; 12(4).

PMID: 36836085 PMC: 9964480. DOI: 10.3390/jcm12041550.

Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.

Sugimoto H, Ogawa T, Iwabuchi Y, Otsuka K, Nitta K Int Urol Nephrol. 2013; 46(1):99-106.

PMID: 23355029 DOI: 10.1007/s11255-013-0386-2.

Fracture risk assessment in patients with chronic kidney disease.

Jamal S, West S, Miller P Osteoporos Int. 2011; 23(4):1191-8.

PMID: 21901475 DOI: 10.1007/s00198-011-1781-0.

The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis.

Saito O, Saito T, Asakura S, Sugase T, Ito C, Ando Y Clin Exp Nephrol. 2010; 15(1):126-31.

PMID: 21069410 DOI: 10.1007/s10157-010-0366-0.

References

Weber T, Liu S, Indridason O, Quarles L . Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003; 18(7):1227-34. DOI: 10.1359/jbmr.2003.18.7.1227. View

Mehrotra R . Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. J Ren Nutr. 2006; 16(2):100-18. DOI: 10.1053/j.jrn.2006.01.006. View

Liu S, Zhou J, Tang W, Jiang X, Rowe D, Quarles L . Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006; 291(1):E38-49. DOI: 10.1152/ajpendo.00008.2006. View

Qunibi W, Abouzahr F, Mizani M, Nolan C, Arya R, Hunt K . Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes. Kidney Int. 2005; 68(1):271-7. DOI: 10.1111/j.1523-1755.2005.00402.x. View

Stubbs J, Liu S, Tang W, Zhou J, Wang Y, Yao X . Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007; 18(7):2116-24. DOI: 10.1681/ASN.2006121385. View

Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T . Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 2006; 69(3):531-7. DOI: 10.1038/sj.ki.5000020. View

. I. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: update 2000. Am J Kidney Dis. 2001; 37(1 Suppl 1):S7-S64. DOI: 10.1016/s0272-6386(01)70005-4. View

Inoue Y, Segawa H, Kaneko I, Yamanaka S, Kusano K, Kawakami E . Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J. 2005; 390(Pt 1):325-31. PMC: 1184586. DOI: 10.1042/BJ20041799. View

Gutierrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359(6):584-92. PMC: 2890264. DOI: 10.1056/NEJMoa0706130. View

10.

Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T . Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005; 289(5):F1088-95. DOI: 10.1152/ajprenal.00474.2004. View

11.

Sitara D, Razzaque M, Hesse M, Yoganathan S, Taguchi T, Erben R . Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004; 23(7):421-32. PMC: 2894977. DOI: 10.1016/j.matbio.2004.09.007. View

12.

Urena Torres P, Friedlander G, De Vernejoul M, Silve C, Prie D . Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2007; 73(1):102-7. DOI: 10.1038/sj.ki.5002622. View

13.

Khachigian L . Early growth response-1 in cardiovascular pathobiology. Circ Res. 2006; 98(2):186-91. DOI: 10.1161/01.RES.0000200177.53882.c3. View

14.

Marsell R, Mirza M, Mallmin H, Karlsson M, Mellstrom D, Orwoll E . Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int. 2008; 20(7):1167-73. DOI: 10.1007/s00198-008-0780-2. View

15.

Portale A, Booth B, Halloran B, Morris Jr R . Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984; 73(6):1580-9. PMC: 437069. DOI: 10.1172/JCI111365. View

16.

Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson K . Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64(6):2272-9. DOI: 10.1046/j.1523-1755.2003.00328.x. View

17.

Sitara D, Kim S, Razzaque M, Bergwitz C, Taguchi T, Schuler C . Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 2008; 4(8):e1000154. PMC: 2483943. DOI: 10.1371/journal.pgen.1000154. View

18.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G . Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16(7):2205-15. DOI: 10.1681/ASN.2005010052. View

19.

Mirams M, Robinson B, Mason R, Nelson A . Bone as a source of FGF23: regulation by phosphate?. Bone. 2004; 35(5):1192-9. DOI: 10.1016/j.bone.2004.06.014. View

20.

Baum M, Schiavi S, Dwarakanath V, Quigley R . Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int. 2005; 68(3):1148-53. DOI: 10.1111/j.1523-1755.2005.00506.x. View